![]() R J is selected from the group consisting of H, Ci-C- talkyl, Cs-Ciocycloalkyl, and 4 to 12-membered helerocyciyl, wherein the Ci-C4alkyl and Cs-Ciocycloalkyl are each optionally substituted with 1 to 4 R c, wherein the 4 to 12-membered heterocyclyl has 1 to 4 ring heteroatoms each independently selected from the group consisting of O, S and NR d and then is optionally substituted on a ring carbon with 1 to 4 R c or R 2 is Cj-CUalkyl or Ring A, wherein the Ci-Crialkyl is optionally substituted with 1 to 4 groups each independently selected from halo, CN, and OH and/or 1 group of 5 to 6 membered heteroaryl having 1 to 3 ring heteroatoms each independently selected from the group consisting of O, S and NR“ and R 1 is Cj-CUalkyl optionally substituted with 1 to 4 halo GOODMANGILMAN: "The Pharmacological Basis of Therapeutics", 2014, MACK PUBLISHING CO. MOLENAAR ET AL., PROC NATL ACAD SCI USA, vol. "The United States Pharmacopeia: The National Formulary", 1999 "Remington's Pharmaceutical Sciences", 2003 TADESSE ET AL., DRUG DISCOVERY TODAY, vol. SILVIA SCHENONE ET AL: "Biologically Driven Synthesis of Pyrazolopyrimidines As Protein Kinase Inhibitors: An Old Scaffold As a New Tool for Medicinal Chemistry and Chemical Biology Studies", CHEMICAL REVIEWS, (), XP055124838, ISSN: 0009-2665, DOI: 10.1021/cr400270z ![]() ZHANG MENGNA ET AL: "CDK inhibitors in cancer therapy, an overview of recent development", AMERICAN JOURNAL OF CANCER RESEARCH, (), US, pages 1913 - 1935, XP055957487, ISSN: 2156-6976, Retrieved from the Internet JEAN-YVES LE BRAZIDEC ET AL: "Synthesis, SAR and biological evaluation of 1,6-disubstituted-1-pyrazolopyrimidines as dual inhibitors of Aurora kinases and CDK1", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM NL, vol. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |